<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pegcetacoplan (ophthalmic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pegcetacoplan (ophthalmic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pegcetacoplan (ophthalmic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="140825" href="/d/html/140825.html" rel="external">see "Pegcetacoplan (ophthalmic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58591965"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Pegcetacoplan Ophthalmic Injection Kit Update</span>
<span class="collapsible-date">August 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Apellis Pharmaceuticals has provided an update on Syfovre (pegcetacoplan) ophthalmic injection kits and an update on the rare events of retinal vasculitis reported in real-world treatment with pegcetacoplan injections for geographic atrophy secondary to age-related macular degeneration. Retinal vasculitis is a rare side effect occurring at an estimated rate of 0.01% per injection. As part of a comprehensive investigation into real-world safety events, internal structural variations were identified in the specific 19-gauge × 1 ½-inch filter needle in certain pegcetacoplan ophthalmic injection kits. A causal relationship has not been established between the structural variations in the 19-gauge filter needle and retinal vasculitis; however, Apellis recommends that providers immediately discontinue use of any kits that contain the 19-gauge filter needle and use kits with 18-gauge filter needles. Apellis is now exclusively distributing kits with 18-gauge filter needles.</p>
<p style="text-indent:0em;">Further information can be found at https://investors.apellis.com/news-releases/news-release-details/apellis-provides-updates-injection-kits-and-rare-safety-events and https://syfovreecp.com/
                        </p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57905496"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Syfovre</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57889500"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Complement C3 Inhibitor;</li>
<li>
                        Complement Inhibitor;</li>
<li>
                        Ophthalmic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F58262538"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Ocular hypotensive medications may be administered if needed to lower intraocular pressure prior to administration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="38082286-fb94-495f-8c9b-aa4e3c8fc071">Geographic atrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Geographic atrophy: Intravitreal:</b> 15 mg (0.1 mL) into affected eye(s) once every 25 to 60 days.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58262540"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F58262541"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F58262545"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Intraocular inflammation: Hold pegcetacoplan; may resume once resolved.</p></div>
<div class="block doe drugH1Div" id="F58262539"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F57905663"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Eye discomfort (10% to 13%), macular degeneration (7% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Ophthalmic: Anterior ischemic optic neuropathy (≤2%), conjunctival hemorrhage (8%), increased intraocular pressure (2% to 3%), intraocular inflammation (2% to 4%), punctate keratitis (3% to 5%), retinal hemorrhage (4% to 5%), secondary cataract (4%), vitreous detachment (4% to 6%), vitreous opacity (7% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Ophthalmic: Anterior chamber eye hemorrhage, endophthalmitis, retinal detachment, retinal pigment epithelium tear</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Ophthalmic: Retinal vascular disease (retinal vasculitis) (Apellis Pharmaceuticals 2023)</p></div>
<div class="block coi drugH1Div" id="F57889503"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Ocular or periocular infections; active intraocular inflammation.</p></div>
<div class="block war drugH1Div" id="F58262526"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Endophthalmitis/retinal detachment: Intravitreous injections are associated with endophthalmitis, retinal detachments, retinal tear, and hyphema. Use proper aseptic injection techniques. Instruct patients to report any signs of endophthalmitis (eg, eye pain or redness, photophobia, blurred vision) immediately; manage appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure: Following intravitreal injection, intraocular pressure may increase (acute); onset may be within minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Inflammation: Intraocular inflammation may occur; signs include anterior chamber cells, anterior chamber flare, iridocyclitis, iritis, uveitis, vitreal cells, and vitritis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neovascular age-related macular degeneration: Neovascular (wet) age-related macular degeneration and choroidal neovascularization have been reported. If antivascular endothelial growth factor is required, administer separately from pegcetacoplan.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal vasculitis/retinal vascular occlusion: Retinal vasculitis and/or retinal vascular occlusion have been reported; may occur with the first intravitreal injection; typically occurs in the presence of intraocular inflammation and may result in severe vision loss. Instruct patients to report any changes in vision and discontinue treatment in patients who develop signs of retinal vasculitis and/or retinal vascular occlusion.</p></div>
<div class="block foc drugH1Div" id="F57905497"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Syfovre: 15 mg/0.1 mL (0.1 mL)</p></div>
<div class="block geq drugH1Div" id="F57905495"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57989948"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Syfovre Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15MG/0.1ML (per 0.1 mL): $2,628.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F58262546"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intravitreal:</b> For ophthalmic intravitreal injection only under controlled aseptic conditions. Each vial is used for the treatment of a single eye. Inject slowly until the full 0.1 mL is delivered. Should be administered using a 27 or 29-gauge <sup>1</sup>/<sub>2</sub>-inch sterile needle. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before pegcetacoplan is administered to the other eye. Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure.</p></div>
<div class="block use drugH1Div" id="F57889502"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Geographic atrophy:</b> Treatment of geographic atrophy secondary to age-related macular degeneration.</p></div>
<div class="block mst drugH1Div" id="F58262522"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Pegcetacoplan may be confused with pegaptanib.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57922638"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57922635"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F58262523"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant should use effective contraception during therapy and for 40 days after the last pegcetacoplan dose. Consider the risks and benefits of treatment prior to use in patients who intend to become pregnant.</p></div>
<div class="block pri drugH1Div" id="F58262524"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies following SUBQ dosing, in utero exposure to pegcetacoplan may cause fetal harm. Systemic exposure following intravitreal injection is expected to be lower compared to a SUBQ dose.</p></div>
<div class="block brc drugH1Div" id="F58262525"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pegcetacoplan is present in breast milk following intravitreal injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for systemic absorption, the manufacturer recommends caution be used in patients who are breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F58262548"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure using tonometry prior and immediately following injection; optic nerve head perfusion; signs/symptoms of endophthalmitis or retinal detachment; signs of neovascular age-related macular degeneration or choroidal neovascularization.</p></div>
<div class="block pha drugH1Div" id="F58262531"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pegcetacoplan is a complement inhibitor that acts by binding to complement protein C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.</p></div>
<div class="block phk drugH1Div" id="F58262532"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~1.85 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized by catabolic pathways into small peptides and amino acids.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 4.5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 7 to 14 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: 0.284 L/day.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847722"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Syfovre</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Apellis Pharmaceuticals, Inc. Apellis provides updates on injection kits and rare safety events with SYFOVRE® (pegcetacoplan injection) [written communication]. Apellis Pharmaceuticals, Inc; August 22, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Syfovre.1">
<a name="Syfovre.1"></a>Syfovre (pegcetacoplan) [prescribing information]. Waltham, MA: Apellis Pharmaceuticals Inc; November 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 140818 Version 25.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
